BHB-1893 vs. Placebo for Symptomatic Non-obstructive Hypertrophic Cardiomyopathy (NOBLEHEART-HCM)

November 13, 2026 updated by: Braveheart Bio, Inc.

A Phase 3, Multi-region, Multi-center, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of BHB-1893 in Adults With Symptomatic Non-obstructive Hypertrophic Cardiomyopathy

The main purpose of this trial is to find out whether BHB-1893 works better than placebo in adults with non-obstructive hypertrophic cardiomyopathy (nHCM).

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

600

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 75 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Key Inclusion Criteria:

  • Diagnosed with HCM per protocol-defined criteria
  • NYHA Class II or III at screening visits
  • KCCQ-CSS that meets the protocol-specified criteria at screening visits
  • Adequate acoustic windows for echocardiography

Key Exclusion Criteria:

  • Resting systolic blood pressure (SBP) of >160 millimeters of mercury (mmHg) at screening visits
  • Resting heart rate of >100 beats per minute (bpm) at screening visits
  • Significant valvular heart disease

Additional protocol-defined inclusion and exclusion criteria apply.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: BHB-1893

Participants will receive BHB-1893 twice daily.

Tablets for oral use

Placebo Comparator: Placebo

Participants will receive matching placebo twice daily.

Tablets for oral use

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Change from Baseline in Kansas City Cardiomyopathy Questionnaire - Clinical Summary Score (KCCQ-CSS)
Time Frame: Baseline, Week 36
Baseline, Week 36
Change from Baseline in Peak Oxygen Uptake (pVO2) by Cardiopulmonary Exercise (CPET)
Time Frame: Baseline, Week 36
Baseline, Week 36

Secondary Outcome Measures

Outcome Measure
Time Frame
Percent Change from Baseline in N-terminal pro-B-type Natriuretic Peptide (NT-proBNP) Concentration
Time Frame: Baseline, Week 36
Baseline, Week 36
Percent Change from Baseline in High-sensitivity Cardiac Troponin I (hsc-TnI) Concentration
Time Frame: Baseline, Week 36
Baseline, Week 36
Number of Participants with >=1 Class Improvement in New York Heart Association (NYHA) Class
Time Frame: Baseline to Week 36
Baseline to Week 36
Change from Baseline in Left Atrial Volume Index (LAVI)
Time Frame: Baseline, Week 36
Baseline, Week 36

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Study Director: Study Director, Braveheart Bio, Inc.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

December 1, 2026

Primary Completion (Estimated)

December 1, 2029

Study Completion (Estimated)

January 1, 2030

Study Registration Dates

First Submitted

November 13, 2026

First Submitted That Met QC Criteria

November 13, 2026

First Posted (Actual)

November 18, 2026

Study Record Updates

Last Update Posted (Actual)

November 18, 2026

Last Update Submitted That Met QC Criteria

November 13, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • BHB-1893-302
  • 2026-527471-29-00 (Ctis)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.